PhD studentship at the Asthma UK Centre for Applied Research (AUKCAR):

Are anonymised databases truly anonymous? PhD Medical Informatics – Part time: 6 years Ref: AUKCAR-17-01a

Evaluating Re-Identification Risks scores in Publicly Available Clinical Trial Datasets: Insights and Implications

07 June 2024

By Aryelly Rodriguez, Steff Lewis, Sandra Eldridge, Tracy Jackson, Chris Weir



Asthma UK Centre

for Applied Research



ASTHMA+

THE UNIVERSITY of EDINBURGH This work is funded by CMVM/UoE. This work is carried out with the support of the Asthma UK Centre for Applied Research [AUK-AC-2012-01]. aukcar.ac.uk @AUKCAR @AryellyR



EDITORIALS

Mandatory data and code sharing for research published by *The BMJ*

New policy requires authors to share analytic codes from all studies and data from all trials

Elizabeth Loder, Helen Macdonald, Theodora Bloom, Kamran Abbasi




From 1 May 2024



Spectrum of identifiability

Asthma UK Centre for Applied Research



Do we know if these datasets pose a privacy risk for participants?





How anonymisation should be done?

Clinical Trials



2.599 Impact Factor 5-Year Impact Factor 2.989 Journal Indexing & Metrics »


Current recommendations/practices for anonymising data from clinical trials in order to make it available for sharing:

A scoping review First published online June 22, 2022

Aryelly Rodriguez (D) 🖂, Christopher Tuck, [...], and Christopher J Weir (D) (+5) View all authors and affiliations









Datasets Variables Assessment

Asthma UK Centre for Applied Research


THE UNIVERSITY of EDINBURGH



Hrynaszkiewicz et al. 28 items of personal and clinical information (UK and Europe)							
Direct Identifier -Indirect Identifier -RemoveCarefully check							
 Name Initials Date of birth 	 Sex Place of birth Occupation Place of work Ethnicity 						

Re-identification risks scores Calculation

Guide to the De-Identification of Personal Health Information






aukcar.ac.uk

Prosecutor Scenario





Prosecutor Scenario - Example


3 indirect identifiers					Description	Va
Race	Age	Sex			All Patients	53
		Male	Female		All unique groups	8
White	>=18 and <70 years	95	28		Maximum Risk	25
	>+70	233	137		Average Risk	
Other	>=18 and <70 years	19	4	V		
	>+70	13	8		Groups above 20%	-
					People on groups above 20%	Z

Above 20% Threshold Risk 0.7%



Re-identification risks scores – Results





39 Controlled / 31 Open 300K participants



aukcar.ac.uk

Re-identification risks scores – Results – All 70 Datasets

@AryellyR

	Mean	Median	Min	Max
No. of participants	4404	355	>10	>25000
No. of variables	968	237	>9	>20000
No. of indirect identifiers	4.2	4	0	>8
Above 20% Threshold Risk	79%	100%	0%	100%
Maximum Risk	91%	100%	0%	100%
Average Risk	74%	95%	0%	100%





- Re-identification risk scores:
 - Feasible and high in magnitude
 Not affected by type access
 Do not describe the actual risk
 Could help inform the data sharing process



Risk Calculation – Next step

aukcar.ac.uk @AUKCAR @AryellyR

Is this going to help someone, or is it already in use?




Online Survey

UK researchers' views regarding their experiences with anonymisation





Asthma UK Centre for Applied Research





Many thanks to my funders



Asthma UK Centre for Applied Research





my supervisors:

Prof S Lewis (University of Edinburgh) <u>steff.lewis@ed.ac.uk</u> Prof C Weir (University of Edinburgh) <u>christopher.Weir@ed.ac.uk</u> Prof S Eldridge (Queen Mary University of London) <u>s.eldridge@qmul.ac.uk</u> Dr T Jackson (University of Edinburgh) <u>Tracy.Jackson@ed.ac.uk</u>

and my husband and children





Thank you! Any questions?

Asthma UK Centre for Applied Research ASTHMA+ LUNG UK



THE UNIVERSITY of EDINBURGH

N.